Answers are grounded in this paper and cite their sources.
Lung cancer remains the leading cause of cancer-related mortality worldwide, traditionally attributed to tobacco smoking. However, lung cancer in non-smokers (LCINS) is increasingly recognized as a distinct clinical and biological entity, currently affecting an estimated 350,000–625,000 individuals globally. This narrative review synthesizes recent literature on the epidemiology, etiology, and management of LCINS. We examine the contributions of sex, ethnicity, environmental pollutants (particulate matter, radon, cooking oil vapors, second-hand smoke), and comorbid lung diseases to LCINS risk. Molecular profiling reveals a landscape dominated by targetable driver alterations, including EGFR, ALK, or other supporting mutations in genes ROS1, RET, KRAS, TP53, and HER2, along with distinct mutational signatures and evolutionary trajectories compared with smoking-related tumors. We further discuss emerging diagnostic strategies and therapeutic approaches, including targeted tyrosine kinase inhibitors or immune checkpoint inhibitors. Our findings support classifying LCINS as a biologically distinct subtype of lung cancer rather than simply lung cancer in the absence of tobacco exposure, with implications for screening criteria and personalized treatment strategies. Further research is needed to clarify its multifactorial origins.
No takes yet. Share an insight, caveat, or question.
Cieślik-Wolski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: